@Pharmdca You realize your sharing the post of Shkreli who was fined millions and jailed for securities fraud? And sana market cap is over 1B now? And they have "data" from 1 patient? And they'll have no product for a very, very, very long time if ever?
@RyanLee11978@Colecalciferol1 They'll have an FDA decision for dialysis access in about 1 year, company estimates 1.3B peak sales from that indication. They won't be stagnant with only 1 indication permanently
@JKeynesIonQ Funny thing is, Shkreli originally argued they would never gain FDA approval. When that happened, his new argument is they'll never sell it. I'm sure he'll come up with something new after a DOD contract lands... Fact is he got lucky FDA delayed and insider was selling
@JKeynesIonQ@RealTimShady42 I expect the company's estimate of 0.6 billion per year figured DOD into it and I expect a contract from the them to be one of the first and largest orders this year, considering they were the impetus behind early review (FDA fumbled) and helped fund research
@JKeynesIonQ@RealTimShady42 I haven't seen any numbers on DOD specifically, but they should be one of the top customers along with trauma locations across the u.s. they expire after 18 or 19 months so there will be recurring revenue even if they're not used.
@Pharmdca $HUMA looks great after approval of their first indication last week. Price targets 15-25 and trading under 5. Next indication likely done in one year, total near 2B peak sales. Market cap 1/4 of that and better indications in the pipe
$HUMA shorts have been extremely lucky between Dugan selling and the FDA delays. Now instead of cashing out, their hubris says the FDA is wrong, the DOD is wrong, 5+ analysts are wrong, surgeons are wrong, studies are wrong, etc etc. Hubris.
$HUMA shorts have moved from 'the FDA won't approve' to 'no one will buy the product'. Obviously, these folks are clueless, but at this juncture, the more shorts, the better. There will be more positive news in the near term. @MartinShkreli
$HUMA estimating 12B+ peak sales after getting additional indications approved, which is now exceedingly likely after first approval. market cap is 570M. They're getting 40M dropped in their lap after a recent raise, plenty of cash. PTs 10-25. GL to the ignorant shorts.
@lordwilmehr Is there an ETA on FL deciding who to reward this contract to? Seems this company is losing $$$ annually hence the share price. No doubt a contract worth 300 M would change their future, but are they the likely choice?
@TRHLofficial 🤣🤦��️ my wife joins you in the seeming minority of women. Natural aging is beautiful, the other option is obviously fake. Well stated and thanks for the laugh, "newborn baby" 🤣😹🤣
Big shoutout to @RevShark for the $AEHR recommendation and discussing the play over the past weeks at @SharkInvesting . Happened to be his stock of the week pick yesterday morning as well - up 17% currently in a very red market
@GeorgiusIIIRex I think it's all just a reference to telling investors there would be no raise and then one happened the next day. I don't know if the CFO was at fault, but that seems to be what the company is saying without pointing their finger
@donmurphy12a@cannacapadvisor@TheDalesReport There it is, innocent until proven guilty and this is also political, takedown by any means necessary means weoponizing judicial system for talking points